European Patent for Teva’s Copaxone Upheld by UK Court

Yeda, the Tech Transfer Company of the Weizmann Institute has a patent for glatiramer acetate which is exclusively licensed to Teva. The pharmaceutical is marketed as Copaxone and used to treat multiple schlerosis (MS).

Mylan challenged the validity of the European patent EP 07862888  which, after a 13 day trial has been upheld by Mr Justice Arnold (Patents Court, England and Wales) in Generics (t/a Mylan) v Yeda and Teva [2012] EWHC 1848 (Pat).

For more details on this development, I refer readers to the IPKAT here.

We note that the US patent was recently upheld – see our previous post here for more details.

 

One Response to European Patent for Teva’s Copaxone Upheld by UK Court

  1. […] EWHC (Pat): Glatiramer acetate patent valid and infringed: Generics (t/a Mylan) v Yeda (IPKat) (PatLit) (The IP Factor) […]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: